Earnings Call/Transcript
Suraksha Diagnostic Q2 FY27 Earnings Call Transcript
Suraksha Diagnostic disclosed the text transcript of its November 13, 2026 earnings call covering Q2 and H1 FY27 results and business updates.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
2
Neutral
6
Bullish
6
Bearish
14
Neutral
6
Bullish
26
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
Healthcare Services
Healthcare Service Provider
1,738 Cr
Low Risk
42.20
60.90
2.36
6.54
381.10
224.10
Sales CAGR
Profit CAGR
ROE
ROCE

View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Earnings Call/Transcript
Suraksha Diagnostic disclosed the text transcript of its November 13, 2026 earnings call covering Q2 and H1 FY27 results and business updates.
Earnings Call/Transcript
Suraksha Diagnostic released the audio recording of its 13 November 2026 earnings call on unaudited results for the quarter and half year ended 30 September 2026.
Investor Presentation
Suraksha Diagnostic released its Q2 and H1 FY27 investor presentation, reporting strong growth and scheduling an earnings call for November 13, 2026 at 11:00 AM IST.
Financial Results
Suraksha Diagnostic corrected operational metrics in its Q2 and H1 FY27 press release, reporting Q2 PAT growth of 69% year-on-year and H1 PAT growth of 54%.
Regulatory/Compliance Filing
Suraksha Diagnostic said its financial results advertisement was not published in Pune and Ahmedabad editions due to regional public holidays, despite timely submission to the newspaper agency.
Suraksha Diagnostic Ltd (SURAKSHA) is currently trading at 333.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Suraksha Diagnostic Limited operates integrated diagnostic centres across Eastern India, combining pathology, radiology, medical consultations, home collection, and online-offline healthcare services. Its network offers routine and specialized pathology, advanced radiology including MRI and CT, and consultation access through 43 centres housing 120 polyclinic chambers and more than 750 doctors. Q2 FY27 revenue crossed INR100 crore, rising 26.4% year on year to INR1,005.7 million, while EBITDA grew 45.5% and PAT increased 69%. The striking feature was operating leverage: EBITDA margin expanded to 36.7% from 31.7%, even as the company continued opening centres and entering new geographies. Suraksha Diagnostic Limited’s mature centres generated a 42% EBITDA margin in Q2 FY27, while centres under two years old improved to 11.8% from negative 16.8% a year earlier. This maturity curve is central to the company’s model, with management expecting ageing centres to offset expansion-related costs and support a 34%–35% steady-state margin. The company is shifting growth from pricing toward patient acquisition, test intensity, and higher-value diagnostics. Revenue per patient reached INR2,348 in Q2, supported by advanced and genomic tests, but management expects this metric to remain broadly stable as B2B business expands; future growth therefore depends mainly on centre additions, volumes, and utilization. Genomics remains small but strategically important, with planned capabilities spanning prenatal diagnostics, inherited diseases, pharmacogenomics, oncology panels, whole-genome testing, metagenomics, and AI integration. Suraksha Diagnostic Limited is attempting to develop Eastern India’s underpenetrated genomics ecosystem through in-house testing, physician engagement, hospital relationships, and its Fetomat platform.
Over the past 52 weeks, Suraksha Diagnostic Ltd has traded between a low of ₹224.10 and a high of ₹381.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Suraksha Diagnostic Ltd has a market capitalization of approximately 1,807.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Suraksha Diagnostic Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 43.87 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,807.46 Cr, Suraksha Diagnostic Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Suraksha Diagnostic Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Suraksha Diagnostic Ltd is 43.87. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Suraksha reported Q2 FY27 PAT of Rs 14.95 crore, up 69% year on year from Rs 8.828 crore. Its PAT margin for the quarter was 15.1%.
Suraksha Diagnostic reported profit after tax of INR149.5 million in Q2 FY27. This was 69% higher than INR88.28 million in Q2 FY26, and the PAT margin was 15.1%.
Suraksha lists nine centres launched in FY27 to date and 11 as upcoming, for 20 centres in total. The launched group comprises three hubs and six spokes, while the pipeline comprises four hubs and seven spokes.
Suraksha’s FY27 timeline states that it has 77+ centres. Its 30 September 2026 operating-network slide lists 19 hubs, 12 medium spokes, 40 small spokes and six PPP locations, which total 77 locations.
